Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lebrikizumab with/without TCS in Moderate-to-Severe Atopic Dermatitis
NCT06280716Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Apr 2024
- Primary completion
- Sep 2025
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial of lebrikizumab in atopic dermatitis (AD) (4 cohorts), sponsored by Eli Lilly and Company. Primary endpoints: Eczema Area and Severity Index 75% Reduction at 16 weeks and Investigator Global Assessment Score 0 or 1 at 16 weeks. Started Apr 2024; status: completed.
02
Drugs
lebrikizumab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT06280716.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06280716.